Pharmacologic Tx Should Be Used Sparingly for Reflux in Preemies

Share this content:
Pharmacologic Tx Should Be Used Sparingly for Reflux in Preemies
Pharmacologic Tx Should Be Used Sparingly for Reflux in Preemies

TUESDAY, June 19, 2018 (HealthDay News) -- Conservative measures to control reflux have limited effect on signs of gastroesophageal reflux (GER) in preterm infants, and pharmacologic treatments should be used sparingly, according to a clinical report published online June 18 in Pediatrics.

Eric C. Eichenwald, M.D., from the Children's Hospital of Philadelphia, and colleagues from the American Academy of Pediatrics' Committee on Fetus and Newborn discuss diagnosis and management of GER among preterm infants.

The authors note that most GER episodes among preterm infants are only weakly acidic due to their lower gastric acidity and frequent milk feedings, reducing the likelihood of esophageal injury. Signs commonly attributed to GER in preterm infants include feeding intolerance or aversion, poor weight gain, frequent regurgitation, apnea, and desaturation and bradycardia, and behavioral signs; however, the temporal association of these perceived signs with reflux episodes is not supported and they usually improve over time without the need for treatment. There is considerable variability in diagnosis and treatment of GER among preterm infants as diagnosis is usually made in the absence of definitive tests. Conservative measures to control reflux have not been shown to reduce clinically assessed signs of GER. There is a lack of evidence for efficacy of pharmacologic agents and emerging evidence of significant harm; consequently, these agents should be used sparingly, if at all.

"GER is almost universal in preterm infants," the authors write. "As such, it is a normal developmental phenomenon that will resolve with maturation."

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »